166 related articles for article (PubMed ID: 32466976)
1. Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis.
Rossini D; Germani MM; Pagani F; Pellino A; Dell'Aquila E; Bensi M; Liscia N; Moretto R; Boccaccino A; Prisciandaro M; Manglaviti S; Schirripa M; Vivolo R; Scartozzi M; Santini D; Salvatore L; Pietrantonio F; Loupakis F; Falcone A; Cremolini C
Clin Colorectal Cancer; 2020 Sep; 19(3):191-199.e6. PubMed ID: 32466976
[TBL] [Abstract][Full Text] [Related]
2. Tumour location and efficacy of first-line EGFR inhibitors in
Benavides M; Díaz-Rubio E; Carrato A; Abad A; Guillén C; Garcia-Alfonso P; Gil S; Cano MT; Safont MJ; Gravalos C; Manzano JL; Sánchez A; Alcaide J; López R; Massutí B; Sastre J; Martínez E; Escudero P; Méndez M; Aranda E
ESMO Open; 2019; 4(6):e000599. PubMed ID: 31803504
[TBL] [Abstract][Full Text] [Related]
3. Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer.
Kratz JD; Uboha NV; Lubner SJ; Mulkerin DL; Clipson L; Yi Y; Yu M; Matkowskyj KA; LoConte NK; Deming DA
J Natl Compr Canc Netw; 2018 Dec; 16(12):1442-1450. PubMed ID: 30545991
[No Abstract] [Full Text] [Related]
4. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
Demurtas L; Puzzoni M; Giampieri R; Ziranu P; Pusceddu V; Mandolesi A; Cremolini C; Masi G; Gelsomino F; Antoniotti C; Loretelli C; Meriggi F; Zaniboni A; Falcone A; Cascinu S; Scartozzi M
Br J Cancer; 2017 Jul; 117(3):315-321. PubMed ID: 28632725
[TBL] [Abstract][Full Text] [Related]
5. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
[TBL] [Abstract][Full Text] [Related]
6. Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02).
García-Albéniz X; Alonso V; Escudero P; Méndez M; Gallego J; Rodríguez JR; Salud A; Fernández-Plana J; Manzano H; Zanui M; Falcó E; Feliu J; Gil M; Fernández-Martos C; Bohn U; Alonso C; Calderero V; Rojo F; Cuatrecasas M; Maurel J
Oncologist; 2019 Nov; 24(11):e1115-e1122. PubMed ID: 31235483
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of anti-EGFR monoclonal antibodies combined with different chemotherapy regimens in patients with RAS wild-type metastatic colorectal cancer: A meta-analysis.
Sun H; Li Y; Su Y; Wu X; Zhou X; Han J; Li J
J Evid Based Med; 2019 Nov; 12(4):300-312. PubMed ID: 31596544
[TBL] [Abstract][Full Text] [Related]
8. Plasma ctDNA RAS status selects patients for anti-EGFR treatment rechallenge in metastatic colorectal cancer: a meta-analysis.
Vlachou MS; Mauri D; Zarkavelis G; Ntellas P; Tagkas C; Gkoura S; Pentheroudakis G
Exp Oncol; 2021 Sep; 43(3):252-256. PubMed ID: 34591420
[TBL] [Abstract][Full Text] [Related]
9. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
10. Optimization of
Santos C; Azuara D; Garcia-Carbonero R; Alfonso PG; Carrato A; Elez ME; Gomez A; Losa F; Montagut C; Massuti B; Navarro V; Varela M; Lopez-Doriga A; Moreno V; Valladares M; Manzano JL; Vieitez JM; Aranda E; Sanjuan X; Tabernero J; Capella G; Salazar R
Mol Cancer Ther; 2017 Sep; 16(9):1999-2007. PubMed ID: 28626084
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
[TBL] [Abstract][Full Text] [Related]
12. Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
Rimassa L; Bozzarelli S; Pietrantonio F; Cordio S; Lonardi S; Toppo L; Zaniboni A; Bordonaro R; Di Bartolomeo M; Tomasello G; Dadduzio V; Tronconi MC; Piombo C; Giordano L; Gloghini A; Di Tommaso L; Santoro A
Clin Colorectal Cancer; 2019 Jun; 18(2):125-132.e2. PubMed ID: 30846365
[TBL] [Abstract][Full Text] [Related]
13. Anti-Epidermal Growth Factor Receptor Antibody Readministration in Chemorefractory Metastatic Colorectal Cancer.
Kajitani T; Makiyama A; Arita S; Shimokawa H; Oda H; Shirakawa T; Baba E; Esaki T
Anticancer Res; 2017 Nov; 37(11):6459-6468. PubMed ID: 29061833
[TBL] [Abstract][Full Text] [Related]
14. Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
Palmieri LJ; Mineur L; Tougeron D; Rousseau B; Granger V; Gornet JM; Smith D; Lievre A; Galais MP; Doat S; Pernot S; Bignon-Bretagne AL; Metges JP; Baba-Hamed N; Michel P; Obled S; Vitellius C; Bouche O; Saban-Roche L; Buecher B; des Guetz G; Locher C; Trouilloud I; Goujon G; Dior M; Manfredi S; Soularue E; Phelip JM; Henriques J; Vernery D; Coriat R
Oncologist; 2020 Feb; 25(2):e266-e275. PubMed ID: 32043796
[TBL] [Abstract][Full Text] [Related]
15. Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer.
Kim TW; Elme A; Park JO; Udrea AA; Kim SY; Ahn JB; Valencia RV; Krishnan S; Manojlovic N; Guan X; Lofton-Day C; Jung AS; Vrdoljak E
Clin Colorectal Cancer; 2018 Sep; 17(3):206-214. PubMed ID: 29703606
[TBL] [Abstract][Full Text] [Related]
16. Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?
Vera R; Mata E; González E; Juez I; Alonso V; Iranzo P; Martínez NP; López C; Cabrera JM; Safont MJ; Ruiz-Casado A; Salgado M; González B; Escudero P; Rivera F; Pericay C
Int J Colorectal Dis; 2020 Apr; 35(4):739-746. PubMed ID: 32062727
[TBL] [Abstract][Full Text] [Related]
17. Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component.
Moretto R; Morano F; Ongaro E; Rossini D; Pietrantonio F; Casagrande M; Antoniotti C; Corallo S; Marmorino F; Cortiula F; Nichetti F; Borelli B; Zucchelli G; Boccaccino A; Masi G; de Braud F; Falcone A; Cremolini C
Clin Colorectal Cancer; 2019 Jun; 18(2):116-124. PubMed ID: 30952563
[TBL] [Abstract][Full Text] [Related]
18. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
19. Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
Mohamed A; Twardy B; AbdAllah N; Akhras A; Ismail H; Zordok M; Schrapp K; Attumi T; Tesfaye A; El-Rayes B
J Gastrointest Cancer; 2019 Jun; 50(2):269-275. PubMed ID: 29388061
[TBL] [Abstract][Full Text] [Related]
20. Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.
Yamada T; Matsuda A; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Koizumi M; Shinji S; Yokoyama Y; Ohta R; Yoshida H
Int J Clin Oncol; 2020 Aug; 25(8):1523-1532. PubMed ID: 32394048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
